Scope and claims analysis for US Patent 12,606,519 (HPLC impurity-profile limits for a naphthalene carbamate hydrochloride monohydrate)
US 12,606,519 is an unusually narrow, formulation-analytics driven composition-and-quality patent. Its claim set is built around (i) a specific active substance identity (a defined naphthalene carbamate hydrochloride monohydrate) and (ii) highly specific HPLC/analytical conditions used to measure impurity levels at defined relative retention times (RRTs). The patent’s enforceable scope is therefore dominated by whether an accused product’s impurity profile (and the test method used to determine it) maps onto the claim language, not by broader synthesis or therapeutic-use coverage.
United States Patent 12,606,519 claims scope: what exactly is protected?
Short answer: The patent protects a specific drug substance (and its monohydrate salt form) meeting defined impurity thresholds under a defined HPLC method, plus dependent claims narrowing detector, buffer, temperature, and measurement parameters.
Independent claim 1: “quality by analytical test” for a defined API monohydrate
Claim 1 is anchored on:
- Specific chemical species (identity limitation)
- “{6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate hydrochloride monohydrate”
- Two alternative quality/impurity regimes (this is critical for scope)
- A defined HPLC method (test-method limitation)
Claim 1 explicitly recites operating conditions and the RRT determination approach. This turns the patent into a “measured attribute” claim: infringement depends on how the impurity is measured and how RRT is established.
Core HPLC method elements in claim 1
-
Stationary phase: C18 silica particles, carbon load < 9% by weight
-
Mobile phase A: water buffered at pH 3.7–3.8
-
Mobile phase B: methanol buffered at pH 3.7–3.8
-
Gradient program (v/v):
| Time (min) |
% Eluent A |
% Eluent B |
| 0.0 |
75 |
25 |
| 5.0 |
75 |
25 |
| 35.0 |
10 |
90 |
| 40.0 |
10 |
90 |
| 40.1 (end run) |
75 |
25 |
-
Detector: “means of a detector” (broad in claim 1; narrowed in dependent claims)
Practical claim construction impact
- The claim is not just “the API has low impurities.” It is “the API has low impurities as determined by the recited HPLC method using those operating conditions and RRT windows.”
- Any enforcement strategy will require a chemical-analytical bridge: demonstrating that the accused material’s impurities, when measured by the claimed method, fall within the RRT-defined caps.
Dependent claims 2–3: tightening impurity thresholds and overall purity
-
Claim 2:
- Same structure as claim 1 but tightens the “single impurity other than intermediate (I) or amide (la)” limit to ≤ 0.10% (from ≤ 0.15% in claim 1’s Route B).
-
Claim 3:
- Adds a purity threshold: “purity equal to or greater than 99.6%.”
Scope effect: These add additional independent quality constraints, but they still tether to the same defined API and the same impurity framework of claim 1.
Dependent claims 4–5: detector type and wavelength
- Claim 4: detector is UV, MS, or RID.
- Claim 5: specifies a 263 nm UV detector.
Scope effect: The broader claim 1 allows any detector. If an accused assay uses a non-claimed detection mode, the infringement analysis can fail on the dependent claims, while claim 1 might still remain relevant if the detector is not required as a limitation in the asserted claim.
Dependent claims 6–10: further tightening HPLC operational parameters
- Claim 6: buffer is formate-formic acid buffer at pH 3.7–3.8.
- Claim 7: temperature 25 ± 1°C.
- Claim 8: injection volume 5 μL.
- Claim 9: flow rate 0.25 mL/min.
- Claim 10: uses DMSO as diluent for the API (or salt) in the HPLC method.
Scope effect: These are classic “copied method” dependencies common in analytical patents. They shift infringement risk toward manufacturing/testing labs and toward whether the accused testing method matches the claimed method parameters.
Which impurities and RRT windows define infringement risk under US 12,606,519?
RRT-based impurity list in claim 1 (closed set)
Claim 1 requires the unidentified impurity be selected from four RRT windows. That is a strong narrowing feature:
| Unidentified impurity “bucket” |
RRT window (±0.02) |
| Impurity 1 |
0.91 to 0.95 |
| Impurity 2 |
1.19 to 1.23 |
| Impurity 3 |
1.49 to 1.53 |
| Impurity 4 |
1.73 to 1.77 |
Enforcement implication: If a competitor’s impurity peak is outside these RRT windows under the claimed method, it may not satisfy the “selected from” limitation as written.
Alternative “other than intermediate (I) or amide (la)” cap
The claim also includes an alternative that does not require mapping to the RRT buckets, but it uses different structure in the limitation:
- “any single impurity other than intermediate (I) or amide (la) ≤ 0.15%”
- dependent claim tightens this to ≤ 0.10%.
Enforcement implication: A key dispute point becomes whether the accused impurity is correctly classified as “intermediate (I)” or “amide (la)” versus a generic “other” impurity. If classification is contestable, infringement can become a chemistry-and-documentation fight (lab method, impurity naming, reference standards).
How strong is the patent estate for US 12,606,519: what is the practical enforceability?
The patent is method-and-attribute limited, not a broad process or therapeutic-use monopoly
From the claim language, US 12,606,519 does not read like:
- a synthesis/process patent (no steps or reagents are claimed),
- a dosage-form or finished product patent (no tablets/capsules/controlled release language),
- a method-of-use patent (no clinical or therapeutic endpoints).
Instead, it reads like:
- a drug-substance quality patent,
- enforced through impurity profiling with an explicit HPLC method and explicit RRT windows.
Net effect: The claim is enforceable if and only if the accused substance, when tested, matches the claimed impurity constraints and method limitations for the asserted claim.
Copying and workarounds: what changes could avoid a literal hit?
Because claims include:
- RRT ranges tied to a specific method,
- specific mobile-phase pH,
- specific gradient profile,
- specified temperature, injection volume, flow rate,
- specific buffer identity for dependent claims,
- specific UV wavelength for one dependent claim,
a laboratory that uses materially different chromatography conditions or detection might avoid certain dependent-claim limitations.
But claim 1 is still anchored to a specific chromatography method and RRT determination scheme, so complete avoidance typically requires changes that move RRT mapping out of the defined windows or shift impurity quantification so that it no longer meets the “as determined” criteria.
What formulations are covered by US 12,606,519 (API vs finished dosage forms)?
Direct answer: The claims cover drug substance in the specific salt form: hydrochloride monohydrate. The claim does not expressly cover polymorphs other than the monohydrate, nor does it expressly claim formulations or dosage forms.
Drug-substance identity limitation
The repeated presence of “carbamate hydrochloride monohydrate” indicates:
- hydrate state is limiting,
- salt form is limiting,
- stereochemistry and exact structure are embedded in the IUPAC-like naming.
Dosing form gaps
No claims are visible here for:
- tablet/capsule composition,
- excipient blends,
- amorphous vs crystalline state,
- particle size or morphology.
That absence narrows use in typical generic entry strategies (which often target API quality, but via different patents and regulatory submissions).
Where does this patent sit in regulatory/Orange Book logic for generic competition?
Key issue: Without the Orange Book listing for the relevant NDA/ANDA and without the actual patent-to-product mapping shown in the Orange Book, the regulatory status cannot be reliably determined from the claim text alone. The claim’s focus is drug-substance analytics, which in practice often correlates with patents listed as drug-substance or method/purity patents.
Paragraph IV / ANDA risk profile: what generic entry risks follow from this claim set?
Risk driver: drug-substance impurity acceptance and testing
For an ANDA applicant, the patent is most relevant if the application uses the same API form and if the applicant’s internal/QC HPLC method (and resulting impurity classification) can be shown to meet or fall outside the claimed caps when measured under the claimed method.
A typical litigation framing would be:
- claim construction around “as determined by HPLC” and RRT determination,
- expert comparison of impurity profiles under claimed method parameters,
- impurity identification/classification disputes for “intermediate (I)” and “amide (la).”
Practical exposure: challenges are fact- and method-heavy
Because the claim is analytical, the strength of enforcement often depends on:
- whether a court/technical tribunal treats the method parameters as exact limitations (likely, given claim recitation),
- whether differences in sample prep, diluents, gradients, or temperature are treated as non-equivalent,
- whether alternative chromatographic methods could still produce the same RRT mapping and impurity quantitation.
How many patents protect this same product quality space?
No landscape count can be produced from the claim text alone. A complete “how many patents” analysis requires an enumeration of all related US patents, their claim scopes, and whether they are listed for the same listed drug. Under the provided constraints, that cannot be completed accurately.
Claim-by-claim infringement map: what would need to be shown
Below is a practical checklist aligning each limitation to evidentiary proof requirements.
| Claim |
Must prove (high-level) |
Evidence type |
| 1 |
Exact API identity and monohydrate hydrochloride form; impurity threshold (≤0.10 area% for one of four RRT windows) and/or single impurity other than intermediate I/amide la ≤0.15%; impurity measured by recited HPLC method (column type, pH, gradient, RRT determination). |
Comparative lab testing using claimed method; chromatograms; method validation; reference standards for intermediate I/amide la; assay reports |
| 2 |
Claim 1 plus “other than intermediate I or amide la ≤0.10%.” |
Same as claim 1 plus tighter impurity quantitation |
| 3 |
Claim 1 plus purity ≥99.6%. |
CoA/assay with traceability |
| 4 |
Claim 1 plus detector type UV/MS/RID |
Method documentation |
| 5 |
Claim 4 plus detector is 263 nm UV |
Instrument settings and trace logs |
| 6 |
Claim 1 plus formate-formic acid buffer at pH 3.7–3.8 |
Method SOP |
| 7 |
Claim 1 plus temperature 25 ±1°C |
Instrument settings |
| 8 |
Claim 1 plus injection volume 5 μL |
Method SOP |
| 9 |
Claim 1 plus flow rate 0.25 mL/min |
Pump logs/SOP |
| 10 |
Claim 1 plus DMSO used as diluent in HPLC |
Sample prep records |
HPLC method specificity: what is the scope of the chromatography limitations?
Why pH and gradient matter
RRT values are method-dependent. The claim’s fixed:
- buffer pH range (3.7–3.8),
- specified gradient segments and end-run reset,
- stationary phase carbon-load constraint (<9%),
all aim to lock in RRT mapping and hence which impurity peaks land in the specified RRT windows.
Why DMSO diluent is material
Dependent claim 10 requires DMSO as diluent for the API or salt in the HPLC method. DMSO can alter solubility, peak shape, and baseline behavior. Under litigation, this can become a clear “all-elements” issue for claim 10.
Key Takeaways
- US 12,606,519 protects a specific API salt hydrate: {6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate hydrochloride monohydrate.
- The claims are analytics-and-quality limited: impurity thresholds are measured by a fully specified HPLC method, with RRT windows identifying which “unidentified impurities” are relevant.
- Enforceability is fact- and method-dependent: infringement hinges on impurity quantitation and whether testing is performed under materially the claimed conditions and yields RRT mapping within the stated ranges.
- Dependent claims further narrow the method by detector type (including 263 nm UV), buffer chemistry, temperature, injection volume, flow rate, and DMSO diluent.
FAQs
-
Do the RRT windows apply to all detectors or only the specified HPLC method?
They are tied to “RRT is determined using an HPLC method” with recited chromatographic conditions; detector choices are addressed via dependent claims.
-
Is the “purity ≥99.6%” limitation independent of impurity RRT mapping?
Claim 3 depends on claim 1, so purity adds an additional requirement alongside the claim 1 identity and impurity/test-method framework.
-
Can an impurity peak outside the four RRT windows still infringe claim 1?
Not under the RRT-bucket “selected from the group” limitation, unless the alternative impurity regime in claim 1 (≤0.15% other than intermediate I/amide la) is satisfied.
-
What role do intermediate (I) and amide (la) play in infringement analysis?
They define what is excluded from the “other impurity” cap; classification affects whether the ≤0.15% (or ≤0.10% in claim 2) limitation is met.
-
Does the patent cover tablets or capsules?
The visible claims are directed to the API hydrochloride monohydrate and its HPLC-measured impurity profile, not to finished dosage forms.
References (APA)
No external sources were cited because the request provided only the claim text for US 12,606,519 and no Orange Book listing, prosecution history, or bibliographic patent data to cite.
